REFERENCES
1. Key statistics for prostate cancer. 2024. Available from: https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html [Last accessed on 20 Mar 2025].
3. Wang Y, Li X, You Z. Comparative analysis of the incidence, diagnosis and treatment of prostate cancer between China and the United States. Serican J Med. 2025:2.
4. Prostate Cancer Foundation. 2022. Available from: https://www.pcf.org [Last accessed on 20 Mar 2025].
5. Chen T, Wang M, Chen Y, Liu Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 2024;24:133.
6. Stefanoudakis D, Kathuria-Prakash N, Sun AW, et al. The potential revolution of cancer treatment with CRISPR technology. Cancers. 2023;15:1813.
7. Li YR, Halladay T, Yang L. Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies. J Biomed Sci. 2024;31:5.
8. Logotheti S, Papadaki E, Zolota V, et al. Lineage plasticity and stemness phenotypes in prostate cancer: harnessing the power of integrated “omics” approaches to explore measurable metrics. Cancers. 2023;15:4357.
9. Chen L, Li Q, Wang Y, Zhang Y, Ma X. Comparison on efficacy of radical prostatectomy versus external beam radiotherapy for the treatment of localized prostate cancer. Oncotarget. 2017;8:79854-63.
10. Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42:354-73.
11. Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019;20:1432-43.
12. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008;58:196-213.
13. Talkar SS, Patravale VB. Gene therapy for prostate cancer: a review. Endocr Metab Immune Disord Drug Targets. 2021;21:385-96.
14. Gudenkauf LM, Gray S, Gonzalez BD, Sachdeva A, Autio K. Balancing hormone therapy: mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management. Am Soc Clin Oncol Educ Book. 2024;44:e433126.
15. Dogbey DM, Torres VES, Fajemisin E, et al. Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy. Drug Deliv Transl Res. 2023;13:2719-38.
16. Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys. 2007;68:682-9.
17. Osuchowski M, Osuchowski F, Latos W, Kawczyk-Krupka A. The use of upconversion nanoparticles in prostate cancer photodynamic therapy. Life. 2021;11:360.
18. Runcie KD, Dallos MC. Prostate Cancer immunotherapy-finally in from the cold? Curr Oncol Rep. 2021;23:88.
19. Kanu GA, Parambath JBM, Abu Odeh RO, Mohamed AA. Gold nanoparticle-mediated gene therapy. Cancers. 2022;14:5366.
20. Allami P, Heidari A, Rezaei N. The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma. Front Mol Biosci. 2022;9:1083645.
21. Beach MA, Nayanathara U, Gao Y, et al. Polymeric nanoparticles for drug delivery. Chem Rev. 2024;124:5505-616.
22. Bajpai S, Tiwary SK, Sonker M, et al. Recent advances in nanoparticle-based cancer treatment: a review. ACS Appl Nano Mater. 2021;4:6441-70.
23. Lee NH, You S, Taghizadeh A, Taghizadeh M, Kim HS. Cell membrane-cloaked nanotherapeutics for targeted drug delivery. Int J Mol Sci. 2022;23:2223.
24. Kadry MO, Abdel-Megeed RM. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds. Plos One. 2024;19:e0302264.
25. Zhang H, Qin C, An C, et al. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer. 2021;20:126.
26. Tabibian M, Moghaddam FS, Motevaseli E, et al. Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling. Cell Commun Signal. 2024;22:504.
27. Kumari S, Sharma V, Tiwari R, Maurya JP, Subudhi BB, Senapati D. Therapeutic potential of p53 reactivation in prostate cancer: strategies and opportunities. Eur J Pharmacol. 2022;919:174807.
28. Belete TM. The current status of gene therapy for the treatment of cancer. Biol Targets Ther. 2021;2021:67-77.
29. Altanerova U, Jakubechova J, Benejova K, et al. Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes. Int J Cancer. 2021;148:128-39.
30. Yanagisawa N, Satoh T, Tabata KI, et al. Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer. Asian J Urol. 2021;8:280-8.
31. Dhankhar R, Kawatra A, Mohanty A, Gulati P. Microbial enzymes used in prodrug activation for cancer therapy: insights and future perspectives. Curr Protein Pept Sci. 2021;22:514-25.
32. Mani R, Martin CG, Balu KE, et al. A novel protozoa parasite-derived protein adjuvant is effective in immunization with cancer cells to activate the cancer-specific protective immunity and inhibit the cancer growth in a murine model of colorectal cancer. Cells. 2024;13:111.
33. Li J, Zeng H, Li L, Song M, Dong M. Biomembrane-wrapped gene delivery nanoparticles for cancer therapy. Front Bioeng Biotechnol. 2023;11:1211753.
34. Wang I, Song L, Wang BY, Rezazadeh Kalebasty A, Uchio E, Zi X. Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy. Am J Clin Exp Urol. 2022;10:210-33.
35. Wang F, Li Z, Feng X, et al. Advances in PSMA-targeted therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:11-26.
36. Flugel CL, Majzner RG, Krenciute G, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20:49-62.
37. Escudero-Lourdes C, Alvarado-Morales I, Tokar EJ. Stem cells as target for prostate cancer therapy: opportunities and challenges. Stem Cell Rev Rep. 2022;18:2833-51.
38. Hafron JM, Wilfehrt HM, Ferro C, Harmon M, Flanders SC, McKay RR. Real-world effectiveness of sipuleucel-T on overall survival in men with advanced prostate cancer treated with androgen receptor-targeting agents. Adv Ther. 2022;39:2515-32.
39. Zanotta S, Galati D, De Filippi R, Pinto A. Enhancing dendritic cell cancer vaccination: the synergy of immune checkpoint inhibitors in combined therapies. Int J Mol Sci. 2024;25:7509.
40. Perera Molligoda Arachchige AS. Human NK cells: from development to effector functions. Innate Immun. 2021;27:212-29.
41. Gong Y, Klein Wolterink RGJ, Wang J, et al. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14:73.
42. Bou-Dargham MJ, Sha L, Sang QA, Zhang J. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy. BMC Cancer. 2020;20:572.
43. Liu LL, Skribek M, Harmenberg U, Gerling M. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature. J Immunother Cancer. 2023;11:e005841.
44. Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets. 2014;15:80-9.
45. Han HA, Pang JKS, Soh BS. Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing. J Mol Med. 2020;98:615-32.
46. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56.
47. Kim TJ, Koo KC. Current status and future perspectives of checkpoint inhibitor immunotherapy for prostate cancer: a comprehensive review. Int J Mol Sci. 2020;21:5484.
48. Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146:940-8.
49. Abou-el-Enein M, Elsallab M, Feldman SA, et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Dis. 2021;2:408-22.
51. Pipe SW, Reddy KR, Chowdary P. Gene therapy: practical aspects of implementation. Haemophilia. 2022;28 Suppl 4:44-52.
52. Zu H, Gao D. Non-viral vectors in gene therapy: recent development, challenges, and prospects. AAPS J. 2021;23:78.
53. Weimin S, Abula A, Qianghong D, Wenguang W. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression. Cancer Biol Ther. 2020;21:570-80.
54. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108:479-85.
55. Narayan V, Barber-Rotenberg JS, Jung IY, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724-34.
56. Quinn C, Young C, Thomas J, Trusheim M. MIT NEWDIGS FoCUS Writing Group. Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system. Value Health. 2019;22:621-6.
58. Porter LH, Harrison SG, Risbridger GP, Lister N, Taylor RA. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies. J Steroid Biochem Mol Biol. 2024;243:106571.
59. Ohomoimen G, Oboma YI, Beredugo S, Beredugo L. MutS homolog 2 and MutS homolog 3 genes are equivocal in prostate disease diagnosis: a study from Niger Delta University Teaching Hospital (NDUTH) in Okolobiri, Bayelsa State, Nigeria. Acad J Health Sci. 2024;39:23.
60. Patra D. Polymer-based nanoparticles as efficient non-viral vectors for gene delivery in CAR-T cell therapy. Exon. 2024;1:87-96.
61. Patnaik S, Anupriya. Drugs targeting epigenetic modifications and plausible therapeutic strategies against colorectal cancer. Front Pharmacol. 2019;10:588.
62. Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160-77.
